We are international
Donate
• about myeloma TEXT SIZE   
Ask Dr Durie

ask_dr_durie_banner



Have a question? Submit it to AskDrDurie@myeloma.org!

facebook
googleplus
twitter
youtube


If you have a question to ask Dr. Durie please email us at AskDrDurie@myeloma.org. We review all questions and will do our best to have your question answered by Dr. Durie.  You can also submit your question via one of the social media channels listed above.

 

The IMF has a vast library of information that is of interest to patients, caregivers, healthcare professionals and other interested parties.  

Click here to visit out library.





#Ask Dr. Durie
    next      view all

10.30.14   #AskDrDurie: Is it possible to have short remissions without high-risk features?

Inspired by last week's #AskDrDurie episode in which Dr. Brian Durie of the IMF explained the definition of remission when it comes to  myeloma patients, this new episodes is a follow-up. Here, Dr. Durie explains why a myeloma patient might experience a short remission period, even if high-risk features have not been identified.


10.23.14   #AskDrDurie: What is remission?

In the latest episode of #AskDrDurie, Dr. Brian Durie of the IMF explains what remission means for myeloma patients.


10.16.14   #AskDrDurie: How does the IMF contribute to the myeloma community?

In the latest episode of #AskDrDurie, Dr. Brian Durie addresses a patient who has just learned about the IMF by explaining three key contributions the IMF makes to myeloma research and education.


09.25.14   #AskDrDurie: What is Selinexor

In this week's episode of #AskDrDurie, Dr. Brian Durie of the IMF takes a question from a patient who has relapsing myeloma and is wondering about the new drug Selinexor. Dr. Durie explains what the drug is and how it can be used in myeloma.


09.18.14   #AskDrDurie: Is autologous stem cell transplant still recommended?

In this episode of the IMF’s #AskDrDurie web series, Dr. Brian Durie talks about when and for what kind of myeloma patient an autologous stem cell transplant (ASCT) is recommended.


09.10.14   #AskDrDurie: Has there been any change in recommendations used to treat bone disease in myeloma?

In this week's episode of #AskDrDurie, the IMF's Chairman Dr. Brian Durie answers a patient's question regarding how bone disease in myeloma is treated. He discusses bisphosphonates such as Aredia and Zometa and what the current recommendations are.


09.03.14   #AskDrDurie: If Pomalyst does not produce a full response, what are my options?

In this episode of #AskDrDurie, Dr. Brian Durie explores options for myeloma treatment if a patient isn’t receiving a full response from Pomalyst.


08.27.14   #AskDrDurie: Is there a test available for measuring Minimal Residual Disease, what we call MRD?

In this week's #AskDrDurie, the IMF's Dr. Brian Durie answers a very important question regarding the tests available for measuring Minimal Residual Disease. As you may know, the IMF's Black Swan Research Initiative(R) has been evaluating a new flow test method for this, and it is becoming a new benchmark.


08.13.14   #AskDrDurie: How can Revlimid’s diarrhea side effect be handled?

In this episode of #AskDrDurie, the IMF's Dr. Brian Durie answers a patient's question about dealing with a specific side effect from Revlimid.


08.07.14   #AskDrDurie: Is it okay to take vitamin B12 on the same day as Velcade?

In this episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a myeloma patient’s question about taking a supplement like vitamin B12 on the same day as Velcade.


    next      view all